{
    "name": "reserpine",
    "comment": "Rx",
    "other_names": [
        "Serpasil"
    ],
    "classes": [
        "Antihypertensives",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/serpasil-reserpine-342393",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: unsafe; excreted into breast milk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: unsafe; excreted into breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity, active peptic ulcer, ulcerative colitis, history of depression, history of gallstones; electroconvulsive treatment within 1 week"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in asthma, gallstones, Parkinson's disease, renal impairment, inflammatory bowel disease or history of peptic ulcer disease",
                "Significant mental depression may occur with high doses",
                "Use caution in patients at risk of hypotension",
                "History of gall stones, PUD, ulcerative colitis",
                "Breastfeeding",
                "Avoid during breast-feeding"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "reserpine increases toxicity of deutetrabenazine by pharmacodynamic synergism. Contraindicated. Reserpine binds irreversibly to VMAT2 and the duration of its effect is several days. Wait for chorea to reemerge before administering deutetrabenazine to help reduce the risk of overdosage and major depletion of serotonin and norepinephrine in the CNS. At least 20 days should elapse after stopping reserpine before starting deutetrabenazine. Do not use these drugs concomitantly."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and reserpine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and reserpine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and reserpine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and reserpine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and reserpine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen and reserpine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "berotralstat",
            "description": {
                "common": "reserpine increases levels of berotralstat by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Reduced berotralstat dose to 110 mg/day when coadministered with P-gp inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and reserpine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, reserpine.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "reserpine and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lemborexant, reserpine.\nEither increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Angina",
            "percent": null
        },
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Peripheral edema",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Premature ventricular contractions",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Weight gain",
            "percent": null
        },
        {
            "name": "Thrombocytopenia purpura",
            "percent": null
        },
        {
            "name": "Gynecomastia",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Nightmare",
            "percent": null
        },
        {
            "name": "Nervousness",
            "percent": null
        },
        {
            "name": "Paradoxical anxiety",
            "percent": null
        },
        {
            "name": "Tardive dyskinesia",
            "percent": null
        },
        {
            "name": "GI hypersecretion",
            "percent": null
        },
        {
            "name": "Impotence",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Optic atrophy",
            "percent": null
        },
        {
            "name": "Decreased libido",
            "percent": null
        },
        {
            "name": "Nasal congestion",
            "percent": null
        }
    ]
}